Rheumatology Medical News about IL-6, Tocilizumab, Pediatric rheumatic

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Rapid correction of low vitamin D status in nursing home residents

3. 2008 Exclusive Survey—Earnings: Good news for primary care income

4. Medicare pay-for-reporting effort draws fire from frustrated doctors

5. Allopurinol-induced recurrent dress syndrome: Pathophysiology and treatment

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Targeting interleukin-6 in pediatric rheumatic diseases
Current Opinion in Rheumatology, 08/18/09

De Benedetti F – Study reports that targeting IL-6 activities is an effective approach in the treatment of chronic inflammatory diseases. The long-term benefit and safety of tocilizumab have to be defined in long-term extension studies; the risk/benefit ratio appears to be particularly favorable in systemic juvenile idiopathic arthritis (s-JIA).

Methods

Main objectives of this study were to:
- Describe the most recent data regarding the role of IL-6 in immune and inflammatory responses
- Mode of action and safety information on tocilizumab, the only available IL-6 inhibitor, and
- Discuss recent results on the therapeutic inhibition of IL-6 in pediatric rheumatic diseases

Results

New data on the effects of IL-6 on T and B cells are available
Clinical trials with tocilizumab in adults provide new data on mechanism of action particularly in RA, and safety database
A withdrawal design trial showed marked efficacy in s-JIA
Open label studies or anecdotal reports suggest possible efficacy also in other JIA subtypes, as well as other rheumatic diseases

<< Previous
Cost-effectiveness acceptability curves

Next >>
Type I interferon and lupus

Will treatment of rheumatoid arthritis with an IL-6R inhibitor help facilitate the age of remission?
Expert Opinion on Investigational Drugs, 10/13/09 Relevance Score: 78%

Minimal influence of tocilizumab on IFN-gamma synthesis by tuberculosis antigen
Modern Rheumatology, 11/17/09 Relevance Score: 66%

Switching to the anti-interleukin-6 receptor antibody tocilizumab in rheumatoid arthritis patients refractory to antitumor necrosis factor biologics
Modern Rheumatology, 10/08/09 Relevance Score: 66%

Improving the management of paediatric rheumatic diseases globally
Best Practice & Research: Clinical Rheumatology, 10/28/09 Relevance Score: 65%

Proinflammatory cytokines synergistically enhance the production of chemokine ligand 20 (CCL20) from rheumatoid fibroblast-like synovial cells in vitro and serum CCL20 is reduced in vivo by biologic disease-modifying antirheumatic drugs
Journal of Rheumatology, 10/05/09 Relevance Score: 65%